Lung Cancer Diagnostic Test Market by Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others), Imaging Test ( Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy (Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others), By Cancer Type (Non-small cell lung cancer and Small Cell Lung Cancer), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others) and By Region - Trends, Analysis and Forecast till 2029

Report Code: PMI486322 | Publish Date: May 2024 | No. of Pages: 180

Global Lung Cancer Diagnostic Test Market Companies

  • Abbott
  • Illumina, Inc.
  • Thermo Fischer Scientific
  • QIAGEN
  • Quest Diagnostics Incorporated
  • NeoGenomics
  • NanoString
  • Myriad Genetics Inc.
  • F. Hoffmann-La Roche Ltd
  • Danaher
  • Agilent Technologies, Inc.
  • AstraZeneca
  • Sanofi
  • Janssen Pharmaceuticals, Inc.

Recent News:

  • In October 2023, DELFI Diagnostics launched FirstLook Lung, an Accessible, Accurate New Way to Enhance Lung Cancer Screening through a Routine Blood Test The science of fragmentomics, which has shown that cancer cells are more chaotic than healthy cells and leave behind distinctive patterns and features of cell-free DNA (cfDNA) fragments in the blood upon death, is the foundation of FirstLook Lung.